Cancer Clinical Trial
Official title:
A Randomized Controlled Trial Leveraging Telehealth to Improve Oral Health and Systemic Outcomes Among Cancer Survivors
Verified date | March 2024 |
Source | Georgetown University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The investigators will conduct a 2-arm 6-month randomized clinical controlled trial to evaluate the effectiveness of an oral Telehealth Intervention (THI) in preventing cancer-related oral complications, improving oral health maintenance and oral health related quality of life, and reducing systemic inflammation compared to Usual Care (UC) among unselected cancer survivors.
Status | Not yet recruiting |
Enrollment | 100 |
Est. completion date | August 25, 2027 |
Est. primary completion date | August 25, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 25 Years to 75 Years |
Eligibility | Inclusion Criteria: - male and female cancer survivors who are either = 6 months after competing primary therapy for cancer treatment (N=100) - between 25-75 years of age - all race/ethnic groups - own a smart phone. Exclusion Criteria: - all head and neck/oral cancer survivors - less then 25 years and older than 75 years of age - recurrence/second cancers or undergoing treatment - unable to provide informed consent. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Georgetown University |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | mucositis | The World Health Organization Oral Toxicity Scale rates the anatomical, and function aspects of oral mucositis. The severity of oral ulcers and ability to consume food and liquid is reported on a scale of 0 (no presentation of symptoms) to 4 (not able to tolerate food or liquid diet). Higher scores indicate worse oral mucositis symptomology.
The PROMS questionnaire: Respondents will indicate their level of oral mucositis symptoms on a sliding scale ranging from no experience of a mucositis-related symptoms to complete experience of symptoms. Higher scores indicate worse self-reported mucositis. |
baseline and repeated at 6 and 12 months | |
Primary | gingival inflammation and periodontal disease | Using the modified gingival index, the investigators will rate inflammation of gums on a 5-point Likert Scale ranging from 0 (absence of inflammation) to 4(severe inflammation, marked redness, edema. Higher scores indicate more severe inflammation. | baseline and repeated at 6 and 12 months | |
Primary | tooth decay | Delayed, Missing, Filled Teeth (DMFT) index based on intraoral imaging The DMFT index will be calculated by summing the number of delayed, missing, or filled teeth and dividing this value by the sum of the DMFT values in the study sample. Higher values equate to poorer tooth retention. | baseline and repeated at 6 and 12 months | |
Primary | oral health related quality of life | Oral health Impact Profile (14-item OHIP-14 questionnaire) and the cancer specific oral health questionnaires (EORTC Quality of Life Questionnaires - oral health)
This measure assesses the impact of oral health on overall wellbeing. Respondents will indicate their agreement with a statement (Yes/No). Higher scores indicate a greater impact of oral health on daily life. EORTC- Quality of Life Questionnaires Oral health: For items 1-11, Respondents indicate agreements on a 4-point Likert scale ranging from 1(not at all) to 4(Very much). On items 12-15, respondents indicate dichotomous agreement (Yes/No). Scores are summed and logged transformed to 0-100 scale. Higher scores indicate a better oral health related quality of life and better functioning. |
baseline and repeated at 6 and 12 months | |
Secondary | systemic inflammation | Blood samples will be processed to separate plasma and buffy coat aliquots within two hours and stores at -80 degrees Celsius. The following biomarkers will be identified: C-reactive protein (mg/dL), IL-1 (pg/mL), IL-6 (pg/mL), and TNF-alpha (pg/mL). | baseline and repeated at 6 and 12 months | |
Secondary | overall health related quality of life | EORTC Quality of Life-C30 will assess health-related quality of life. For items 1-28, respondents will indicate agreement on a 4-point Likert scale ranging from 1(Not at all) to 4(very Much). For items 29 and 30, respondents rate agreement on a 7-point Likert scale ranging from 1(very poor) to 7(excellent). Scores are summed and logged transformed to 0-100 scale. Higher scores indicate a better health-related quality of life and better functioning. | baseline and repeated at 6 and 12 months | |
Secondary | comorbidities | Captured via self-report survey, participants will indicate prior or current diagnoses of cardiovascular and metabolic comorbidities including diabetes, hypertension, cardiovascular disease, stroke, etc.
- Anthropometrics Height in centimeters rounded to the nearest tenth. Weight in kilograms, captured on a calibrated scale. Waist circumference in centimeters Hip circumference in centimeters. |
baseline and repeated at 6 and 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
Completed |
NCT04448041 -
CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
|
||
Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|